Takeda-backed Ascentage Pharma sets terms for $170 million IPO


Initial public offering hologram, night panoramic view of Bangkok city. The financial center of multinational companies in Asia. The concept of boosting growth through the IPO process. double exposure

Illustrations and 2D photographs

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK: ASPHF), which is developing treatments for blood cancer, has set terms for a US$170 million initial public offering.

In an SEC filing, Ascentage ( AAPG ) said it plans to offer 7.3 million American Depositary Shares, representing 29.3 million shares of common stock. While the company



Source link

  • Related Posts

    Trump announces private sector $500 billion investment in AI infrastructure By Reuters

    By Steve Holland (Reuters) – U.S. President Donald Trump on Tuesday announced a private sector investment of up to $500 billion to fund infrastructure for artificial intelligence, aiming to overtake…

    That’s why this medical AI stock soared 35% on Tuesday

    Toru Hanai/Bloomberg via Getty Images SoftBank Chairman and CEO Masayoshi Son, center, shakes hands with Tempus AI COO Ryan Fukushima, left, as Tempus AI CEO Eric Lefkofsky appears on a…

    Leave a Reply

    Your email address will not be published. Required fields are marked *